The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.
Tumor-Associated Macrophages: From Mechanisms to Therapy
Open accessAbstract
The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy. Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression. Clinical studies and experimental mouse models indicate that these macrophages generally play a protumoral role. In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation. During monocytes and/or metastasis, macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth. Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy. Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM re-education, and TAM depletion [88, 96, 101, 102].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“Many therapy strategies have attempted to alter the polarization of macrophages’ “re-programming” or prevent monocyte tumor infiltration (Noy and Pollard, 2014).”
From Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review (2021) · cites this paper as Noy and Pollard, 2014
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [167]
In the citing paper
“The production of colony stimulating factor 1 (CSF-1; also known as macrophage colony stimulating factor) by BCCs, has been reported to stimulate the recruitment of macrophages to primary breast tumors, leading to the secretion by tumor-associated macrophages (TAMs) of epidermal growth factor, which binds to its cognate receptor on BCCs to stimulate invasion and metastasis [36–38].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Forget, M. A., Voorhees, J. L., Cole, S. L., Dakhlallah, D. A., Patterson, I. L., Gross, A. C., Moldovan, L., Mo, X. M., Evans, R., Marsh, C. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098623 · Cited by 79 · cited 2×
“Interestingly, CSF1 upregulates TIE2 on TAMs (Forget et al., 2014) indicating a link between CSF1, TIE2 macrophages, and the induction of the angiogenic switch.”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…the ways in which the microenvironmental support to tumors is the acquisition of a vasculature that provides oxygenation, as well as the nutrition and waste disposal required for growth above a certain size in a process often referred to as the ‘‘angiogenic switch’’ (Hanahan and Weinberg, 2011).”
BackgroundCoussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · cited 1×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 4×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundInfluentialMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 3×
“…SPARC) that increases tumor cell-ECM interaction and thus migration (Sangaletti et al., 2008), Cathepsin proteases that remodel the matrix and release sequestered growth factors (Laoui et al., 2011; Quail and Joyce, 2013) and TGF-b that promotes EMT of the invading tumor cells (Bonde et al., 2012).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 1×
“TheseM-MDSCs have greater immunosuppressive potency than the granulocytic ones and are further defined as F4/80+ a marker also found on inflammatory monocytes (Gabrilovich and Nagaraj, 2009; Gabrilovich et al., 2012).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 2×
“References to these polarizing agents can be found in (De Palma and Lewis, 2013; Sica and Mantovani, 2012). above strongly support targeting the destruction or redifferentiation of macrophages as an important part of combinatorial therapies in human cancer patients.”
BackgroundAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“…the activated macrophages responding to IFN-g, TNF-a, and Toll-like receptor 4 (TLR4) activation capable of killing pathogens through mechanisms such as iNOS, and (2) alternatively activated macrophages responding to IL-4 and IL-13 involved in antiparasitic immunity and in asthma (Gordon, 2003).”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,349 · cited 11×
“Furthermore, in most large-scale transcriptome analysis, macrophages have a mixed phenotype expressing both M1 and M2 markers (Qian and Pollard, 2010).”
BackgroundInfluentialSelf-citation
Flagged first, then by citations
2 of the 136 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 1,010
Trends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. H. H. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 215
Chugh, V., Krishna, K. V., & Pandit, A. S. (2021) · ACS Nano · doi:10.1021/acsnano.1c03800 · Cited by 219
Francos-Quijorna, I., Amo‐Aparicio, J., Martínez‐Muriana, A., & López‐Vales, R. (2016) · Glia · doi:10.1002/glia.23041 · Cited by 213
miR‐28‐5p‐IL‐34‐macrophage feedback loop modulates hepatocellular carcinoma metastasis
Zhou, S., Hu, Z., Zhou, Z., Dai, Z., Wang, Z., Cao, Y., Fan, J., Huang, X., & Zhou, J. (2016) · Hepatology · doi:10.1002/hep.28445 · Cited by 211
Zhang, A., Xu, Y., Xu, H., Ren, J., Meng, T., Ni, Y., Zhu, Q., Zhang, W., Pan, Y., Jin, J., et al. (2021) · Theranostics · doi:10.7150/thno.53749 · Cited by 215
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W. Q., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 218
Targeting the RNA m6A modification for cancer immunotherapy
Li, X., Ma, S., Deng, Y., Yi, P., & Yu, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01558-0 · Cited by 212
Hsu, Y., Hung, J., Chang, W., Jian, S., Lin, Y.-S., Pan, Y., Wu, C., & Kuo, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.016 · Cited by 208
Roux, C., Jafari, S. M., Shinde, R. S., Duncan, G. S., Cescon, D. W., Silvester, J., Chu, M. F., Hodgson, K., Berger, T., Wakeham, A. C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819473116 · Cited by 208
Immune cell - produced ROS and their impact on tumor growth and metastasis
Kennel, K. B., & Greten, F. R. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101891 · Cited by 213
Nanomedicine applications in the treatment of breast cancer: current state of the art
Wu, D., Si, M., Xue, H.-Y., & Wong, H. L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s123437 · Cited by 213
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Sun, H., Liu, S. M., Zhou, J., Xu, J., Zhang, H.-K., Yan, H., Huan, J., Dai, P., Xu, C., Su, J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102990 · Cited by 205
Cassetta, L., & Kitamura, T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00038 · Cited by 200
“One of the most successful approaches to mount CD8+ T cellmediated anti-tumor immune reaction is the administration of checkpoint inhibitors, i.e., blocking antibodies against inhibitory checkpoint receptors (e.g., PD-1 and CTLA4) or ligands (e.g., PD-L1) (Farkona et al., 2016; Khalil et al., 2016).”
BackgroundInfluentialMarigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H. R., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.004 · Cited by 205
Looi, C.-K., Chung, F. F., Leong, C., Wong, S. F., Rosli, R., & Mai, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 209
Lung Tumor Cell-Derived Exosomes Promote M2 Macrophage Polarization
Pritchard, A. H. D. I., Tousif, S., Wang, Y., Hough, K. P., Khan, S., Strenkowski, J. G., Chacko, B. K., Darley-Usmar, V. M., & Deshane, J. S. (2020) · Cells · doi:10.3390/cells9051303 · Cited by 205
Oshi, M., Tokumaru, Y., Asaoka, M., Yan, L., Satyananda, V., Matsuyama, R., Matsuhashi, N., Futamura, M., Ishikawa, T., Yoshida, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73624-w · Cited by 209
Wang, X., Tokheim, C. J., Gu, S. S., Wang, B., Tang, Q., Li, Y., Traugh, N. C., Zeng, Z., Zhang, Y., Li, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.006 · Cited by 208
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion
Günaydın, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668349 · Cited by 211
Hypoxic tumor microenvironment: Opportunities to develop targeted therapies
Patel, A., & Sant, S. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.04.005 · Cited by 205
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Tumor-Associated Macrophages as Target for Antitumor Therapy
Sawa-Wejksza, K., & Kandefer‐Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0480-8 · Cited by 207
CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer
Lin, L., Chen, Y.-S., Yao, Y., Chen, J., Chen, J.-N., Huang, S., Zeng, Y., Yao, H., Zeng, S.-H., Fu, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5325 · Cited by 209
Pooled CRISPR screening identifies m 6 A as a positive regulator of macrophage activation
Tong, J., Wang, X., Liu, Y., Ren, X., Wang, A. M., Chen, Z., Yao, J., Mao, K., Liu, T., Meng, F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd4742 · Cited by 202
Roles of macrophages on ulcerative colitis and colitis-associated colorectal cancer
Zhang, M., Li, X., Zhang, Q., Yang, J., & Liu, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1103617 · Cited by 205
MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment
Kohlhapp, F. J., Mitra, A. K., Lengyel, E. R., & Peter, M. E. (2015) · Oncogene · doi:10.1038/onc.2015.89 · Cited by 204
Mei, J., Xiao, Z., Guo, C., Pu, Q., Ma, L., Liu, C., Lin, F., Liao, H., You, Z., & Liu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9079 · Cited by 202
Pan, W. Q., Zhu, S., Qu, K., Meeth, K. M., Cheng, J., He, K., Ma, H., Liao, Y., Wen, X., Roden, C., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.020 · Cited by 202
Zhang, Y., Zuo, C., Liu, L., Hu, Y., Yang, B. R., Qiu, S., Li, Y., Cao, D., Ju, Z., Ge, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.023 · Cited by 207
Mikuła‐Pietrasik, J., Uruski, P., Tykarski, A., & Książek, K. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2663-1 · Cited by 199
Garrido-Martin, E. M., Mellows, T., Clarke, J. D., Ganesan, A.-P., Wood, O., Cazaly, A. M., Seumois, G., Chee, S., Alzetani, A., King, E. V., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000778 · Cited by 206
Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
Xiong, H., Mittman, S., Rodriguez, R., Москаленко, М., Pacheco-Sanchez, P., Yang, Y., Nickles, D., & Cubas, R. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3208 · Cited by 199
Stienstra, R., Netea-Maier, R. T., Riksen, N. P., Joosten, L. A. B., & Netea, M. G. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.001 · Cited by 206
Kulkarni, A. A., Chandrasekar, V., Natarajan, S. K., Ramesh, A., Pandey, P. R., Nirgud, J., Bhatnagar, H., Ashok, D., Ajay, A. K., & Sengupta, S. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0254-6 · Cited by 193
Tumor-Associated-Macrophage-Membrane-Coated Nanoparticles for Improved Photodynamic Immunotherapy
Chen, C., Song, M., Du, Y., Yu, Y. H., Li, C., Han, Y., Yan, F., Shi, Z., & Feng, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00818 · Cited by 196
Yan, D., Wang, H., Bowman, R. L., & Joyce, J. A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.035 · Cited by 194
Han, Y., Guo, W., Ren, T., Huang, Y., Wang, S., Liu, K., Zheng, B., Kang, Y., Zhang, H., & Liang, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.011 · Cited by 190
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
Birgani, M. T., & Carloni, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020405 · Cited by 197
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
Wu, C., Ning, H., Liu, M., Lin, J., Luo, S., Zhu, W., Jing, X., Wu, W.-C., Liang, J., Shao, C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97973 · Cited by 200
Kuen, J., Darowski, D., Kluge, T., & Majety, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182039 · Cited by 192
Occurrence and significance of tumor‐associated neutrophils in patients with colorectal cancer
Galdiero, M. R., Bianchi, P. P., Grizzi, F., Caro, G. D., Basso, G., Ponzetta, A., Bonavita, E., Barbagallo, M., Tartari, S., Polentarutti, N., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30076 · Cited by 197
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 203
Hashimoto, O., Yoshida, M., Koma, Y., Yanai, T., Hasegawa, D., Kosaka, Y., Nishimura, N., & Yokozaki, H. (2016) · The Journal of Pathology · doi:10.1002/path.4769 · Cited by 190
Figueiredo, C. R., Azevedo, R., Mousdell, S., Resende-Lara, P. T., Ireland, L., Santos, A., Girola, N., Cunha, R. L. O. R., Schmid, M. C., Polonelli, L., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01132 · Cited by 190
Argyle, D. J., & Kitamura, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02629 · Cited by 195
Role of the tumor microenvironment in pancreatic cancer
Murakami, T., Hiroshima, Y., Matsuyama, R., Homma, Y., Hoffman, R. M., & Endo, I. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12225 · Cited by 196
Ramesh, A., Kumar, S., Nandi, D., & Kulkarni, A. A. (2019) · Advanced Materials · doi:10.1002/adma.201904364 · Cited by 191
Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer
Masetti, M., Carriero, R., Portale, F., Marelli, G., Morina, N., Pandini, M., Iovino, M., Partini, B., Erreni, M., Ponzetta, A., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210564 · Cited by 202
Shi, C. J., Li, M., Zhang, Z., Yao, Q., Shao, K., Xu, F., Xu, N., Li, H., Fan, J., Sun, W. C., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119755 · Cited by 192
Corpse Engulfment Generates a Molecular Memory that Primes the Macrophage Inflammatory Response
Weavers, H., Evans, I. R., Martin, P. B., & Wood, W. (2016) · Cell · doi:10.1016/j.cell.2016.04.049 · Cited by 190
Caspase-1 cleaves PPARγ for potentiating the pro-tumor action of TAMs
Niu, Z., Shi, Q., Zhang, W., Shu, Y., Yang, N., Chen, B., Wang, Q., Zhao, X., Chen, J., Cheng, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00523-6 · Cited by 191
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
Halaby, M. J., Hezaveh, K., Lamorte, S., Ciudad, M. T., Kloetgen, A., MacLeod, B. L., Guo, M., Chakravarthy, A., Medina, T. D. S., Ugel, S., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aax8189 · Cited by 190
Peter, A. W., Adamson, G. D., Al‐Jefout, M., Becker, C. M., D’Hooghe, T. M., Dunselman, G. A. J., Fazleabas, A. T., Giudice, L. C., Horne, A. W., Hull, M. L., et al. (2016) · Reproductive Sciences · doi:10.1177/1933719116654991 · Cited by 192
Binnemars‐Postma, K., Bansal, R., Storm, G., & Prakash, J. (2017) · The FASEB Journal · doi:10.1096/fj.201700629r · Cited by 188
Zhang, Q., Wang, H., Mao, C., Sun, M., Dominah, G. A., Chen, L., & Zhuang, Z. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.011 · Cited by 188
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer
Faria, S. S., Costantini, S., de Lima, V. C. C., Andrade, V. P., Rialland, M., Rébé, C., Budillon, A., & Magalhães, K. G. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00724-8 · Cited by 192
In vivomodels in breast cancer research: progress, challenges and future directions
Holen, I., Speirs, V., Morrissey, B., & Blyth, K. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.028274 · Cited by 183
Benner, B. N., Scarberry, L., Suarez‐Kelly, L. P., Duggan, M. C., Campbell, A. R., Smith, E., Lapurga, G., Jiang, K., Butchar, J. P., Tridandapani, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0622-0 · Cited by 188
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Bourhis, M., Palle, J., Galy–Fauroux, I., & Terme, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616837 · Cited by 192
NADPH Oxidases Are Essential for Macrophage Differentiation
Xu, Q., Choksi, S., Qu, J., Jang, J., Choe, M., Bánfi, B., Engelhardt, J. F., & Liu, Z.-G. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.731216 · Cited by 188
The roles of CSF s on the functional polarization of tumor‐associated macrophages
Jeannin, P., Paolini, L., Adam, C., & Delneste, Y. (2017) · FEBS Journal · doi:10.1111/febs.14343 · Cited by 192
Osteopontin as a multifaceted driver of bone metastasis and drug resistance
Pang, X., Gong, K., Zhang, X., Wu, S., Cui, Y., & Qian, B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.030 · Cited by 189
Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
Kamber, R. A., Nishiga, Y., Morton, B., Banuelos, A. M., Barkal, A. A., Vences‐Catalán, F., Gu, M., Fernández, D., Seoane, J. A., Yao, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03879-4 · Cited by 179
Fan, J., To, K. K. W., Chen, Z., & Fu, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100905 · Cited by 189
Baghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, N., Putra, W. E., Endo, D., Watari, H., Sakuragi, N., Hida, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1170 · Cited by 188
Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation
Afify, S. M., & Seno, M. (2019) · Cancers · doi:10.3390/cancers11030345 · Cited by 188
Kong, Y., Liu, F., Ma, B., Duan, J., Yuan, W., Sang, Y., Lin, H., Wang, S., & Liu, H. (2021) · Advanced Science · doi:10.1002/advs.202100962 · Cited by 182
Progress on Modulating Tumor‐Associated Macrophages with Biomaterials
Sylvestre, M., Crane, C. A., & Pun, S. H. (2019) · Advanced Materials · doi:10.1002/adma.201902007 · Cited by 183
Characterizing dedifferentiation of thyroid cancer by integrated analysis
Luo, H., Xia, X., Kim, G. D., Liu, Y., Xue, Z., Zhang, L., Shu, Y., Yang, T., Chen, Y., Zhang, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf3657 · Cited by 181
Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide
Scodeller, P., Simón‐Gracia, L., Kopanchuk, S., Tobi, A., Kilk, K., Säälik, P., Kurm, K., Squadrito, M. L., Kotamraju, V. R., Rinken, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14709-x · Cited by 188
Ma, S., Song, W., Xu, Y., Si, X., Lv, S., Zhang, Y., Tang, Z., & Chen, X. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b05265 · Cited by 180
The hallmarks of cancer are also the hallmarks of wound healing
MacCarthy‐Morrogh, L., & Martin, P. B. (2020) · Science Signaling · doi:10.1126/scisignal.aay8690 · Cited by 181
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Yin, M., Guo, Y., Hu, R., Cai, W. L., Li, Y., Pei, S., Sun, H., Peng, C., Li, J., Ye, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15290-0 · Cited by 179
Chen, X., Gao, A., Zhang, F., Yang, Z., Wang, S., Fang, Y., Li, J., Wang, J., Shi, W., Wang, L., et al. (2021) · Theranostics · doi:10.7150/thno.52435 · Cited by 184
Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer
Reichman, H., Itan, M., Rozenberg, P., Yarmolovski, T., Brazowski, E., Varol, C., Gluck, N., Shapira, S., Arber, N., Qimron, U., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0494 · Cited by 178
Revisiting the hallmarks of cancer: The role of hyaluronan
Caon, I., Bartolini, B., Parnigoni, A., Caravà, E., Moretto, P., Viola, M., Karousou, E. G., Vigetti, D., & Passi, A. G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.007 · Cited by 181
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
Zhu, S., Yi, M., Wu, Y., Dong, B., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00252-z · Cited by 179
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect
Nishiga, Y., Drainas, A. P., Baron, M., Bhattacharya, D., Barkal, A. A., Ahrari, Y., Mancusi, R. A., Ross, J., Takahashi, N., Thomas, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00456-0 · Cited by 180
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer HeterogeneityPreprint
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 179
Ontogeny of Tumor-Associated Macrophages and Its Implication in Cancer Regulation
Franklin, R. A., & Li, M. O. (2016) · Trends in cancer · doi:10.1016/j.trecan.2015.11.004 · Cited by 179
Role of tumor‐associated macrophages in human malignancies: friend or foe?
Takeya, M., & Komohara, Y. (2016) · Pathology International · doi:10.1111/pin.12440 · Cited by 178
Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment
Norton, K., Gong, C., Jamalian, S., & Popel, A. S. (2019) · Processes · doi:10.3390/pr7010037 · Cited by 178
Li, Y., Dong, Y., Li, Y., Wang, D., Liu, S., Wang, D., Gao, Q., Ji, S., Chen, X., Lei, Q., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32151 · Cited by 175
Tumor heterogeneity: preclinical models, emerging technologies, and future applications
Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., & Gilardi, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1164535 · Cited by 188
3D Tumor Models and Their Use for the Testing of Immunotherapies
Boucherit, N., Gorvel, L., & Olive, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603640 · Cited by 188
Khoo, B. L., Grenci, G., Lim, Y. B., Lee, S. C., Han, J., & Lim, C. T. (2018) · Nature Protocols · doi:10.1038/nprot.2017.125 · Cited by 172
3D scaffolds in breast cancer research
Rijal, G., & Li, W. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.016 · Cited by 169
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S. E., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 175
Eisinger, S., Sarhan, D., Boura, V. F., Ibarlucea-Benitez, I., Tyystjärvi, S., Oliynyk, G., Arsenian‐Henriksson, M., Lane, D. P., Wickström, S. L., Kiessling, R. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015343117 · Cited by 180
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer
Bronte, V., & Murray, P. J. (2015) · Nature Medicine · doi:10.1038/nm.3794 · Cited by 172
Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer
Peng, L., Zhang, J., Teng, Y., Zhao, Y., Wang, T., Mao, F.-Y., Lv, Y.-P., Cheng, P., Li, W.-H., Chen, N., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0152 · Cited by 172
Ao, J., Zhu, X., Chai, Z., Cai, H., Zhang, Y., Zhang, K., Kong, L., Zhang, N., Ye, B., Ma, D.-N., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0866 · Cited by 173
Li, X., Bu, W.-H., Meng, L., Liu, X.-C., Wang, S.-S., Jiang, L., Ren, M.-S., Fan, Y., & Sun, H.-C. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.03.013 · Cited by 163
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
Chen, D., Ning, W.-R., Jiang, Z.-Z., Peng, Z.-P., Zhu, L., Zhuang, S., Kuang, D., Zheng, L., & Wu, Y. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.007 · Cited by 170
Aging, inflammation and cancer
Bottazzi, B., Ríboli, E., & Mantovani, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.011 · Cited by 170
Salvagno, C., Ciampricotti, M., Tuit, S., Hau, C., van Weverwijk, A., Coffelt, S. B., Kersten, K., Vrijland, K., Kos, K., Ulas, T., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0298-1 · Cited by 168
Pérez‐Medina, C., Tang, J., Abdel-Atti, D., Hogstad, B., Mérad, M., Fisher, E. A. A., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158956 · Cited by 168
Metadata
- Authors
- Noy, R., & Pollard, J. W.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Pollard, Jeffrey W.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 41
- Issue
- 1
- Pages
- 49-61
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC4137410
- OpenAlex
- W1971620413
- Cited by
- 4,089
- References
- 136
- Citations by year
- 2026: 258 · 2025: 326 · 2024: 359 · 2023: 393 · 2022: 485 · 2021: 479 · 2020: 424 · 2019: 379 · 2018: 297 · 2017: 285 · 2016: 215 · 2015: 157 · 2014: 27
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-11-20)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust (101067, 101067/Z/13/Z)
- National Institutes of Health (UL1TR001073)
- National Cancer Institute (P01CA100324, R01CA172451)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-associated macrophages, tumor microenvironment, tumor angiogenesis, tumor invasion, metastasis, pre-metastatic niche, immunosuppression, natural killer cells, T cells, macrophage-targeted therapy, combination cancer therapy
- MeSH terms
- Animals, Cell Movement, Cell Survival, Cell Transformation, Neoplastic, Humans, Immunosuppression Therapy, Macrophages, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Cell Lineage, Cell Proliferation, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
